Zobrazeno 1 - 10
of 114
pro vyhledávání: ''
Autor:
Harish Seethapathy, Paul Endres, Donald P. Lawrence, Meghan E. Sise, David A. Qualls, Halla Bates, Kerry L. Reynolds, Shahein Tajmir, Pedram Heidari
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Background Acute interstitial nephritis is an immune-related adverse event that can occur in patients receiving immune checkpoint inhibitor therapy. Differentiating checkpoint inhibitor-associated acute interstitial nephritis from other causes of acu
Autor:
Chengcheng Li, Shangli Cai, Puyuan Xing, Fan Zhang, Yiying Guo, Yu Xu, Guoqiang Wang, S. Wang, Junling Li, Yan Wang
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Background Deciphering the correlation between immune-related adverse events (irAEs) categorized by organ system class and clinical benefit of immunotherapy is critical for clinical practice. The aim of this study is to investigate the incidence rate
Autor:
Junying Zheng, Rui Wang, Megan Wind-Rotolo, Yan Feng, Richard Lee, Yuko Ishii, Akintunde Bello, Joshua Zhang, Xiao Shao, Amit Roy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Although several therapeutic options for patients with renal cell carcinoma (RCC) have been approved over recent years, including immune checkpoint inhibitors, considerable need remains for molecular biomarkers to assess disease prognosis.
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-5 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Eosinophilia has been reported as a rare, new biological effect of immune checkpoint inhibition that may be associated with improved treatment response and the development of immune-related adverse events. Case presentation We report a cas
Autor:
Christopher Szeto, Sara Lonardi, Andrew Nguyen, Giada Munari, Angelo Paolo Dei Tos, Matteo Fassan, Giulia Maddalena, Fotios Loupakis, Vittorina Zagonel, Sabina Murgioni, Ilaria Depetris, Massimo Rugge, Francesca Bergamo
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Background Analysis of deficiency in DNA mismatch repair (dMMR) is currently considered a standard molecular test in all patients with colorectal cancer (CRC) for its implications in screening, prognosis and prediction of benefit from immune checkpoi
Autor:
Riley Fadden, Gabriel E. Molina, Michael Dougan, Vikram Deshpande, Hui Zheng, Ryan J. Sullivan, Steven T. Chen, Michael S. Hughes
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Background Immune checkpoint inhibitors (CPIs) are effective against a variety of malignancies but can be limited by inflammatory toxicities such as enterocolitis. Enterocolitis is typically treated with systemically active glucocorticoids. Endoscopy
Autor:
Tatjana Vlajnic, Michael Dobbie, Marcus Vetter, Michel Bihl, Katharina Glatz, Florence Baettig, Jürgen Hench, Roberto Lopez, Celine Montavon, Stephan Frank, Viola Heinzelmann-Schwarz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Treatment options for advanced cervical cancer are limited and patients experiencing recurrence after first-line cisplatin-based chemotherapy and bevacizumab have a poor prognosis. A recent phase II study in advanced cervical cancer has de
Autor:
Marcella Fassò, Carol O'Hear, Priti S. Hegde, Yijin Li, Leisha A. Emens, Sophia Maund, Maureen Berg, Jeanne Harrison, Luciana Molinero, Ching-Wei Chang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells. The current study describes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-5 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Hypophysitis is a well-recognized immune-related adverse event in patients treated with immune checkpoint inhibitors for cancer. Some anterior pituitary hormones may recover; however, secondary adrenal insufficiency is usually permanent. C
Autor:
Feng Li, Zhenqiang Sun, Dan Wang, Weitang Yuan, Li Yang, Aitian Li, Jinbo Liu, Zhiang He, Shasha Liu, Jingyao Lian, Weina Yu, Yi Zhang, Qian Wu
Publikováno v:
J Immunother Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Journal for Immunotherapy of Cancer
Background Colorectal cancer (CRC) is one of the most common forms of cancer worldwide. The tumor microenvironment plays a key role in promoting the occurrence of chemoresistance in solid cancers. Effective targets to overcome resistance are necessar